Pharmacokinetics of intravenous diltiazem and five of its metabolites in patients with chronic renal failure and in healthy volunteers

✍ Scribed by Maha Tawashi; Julien Marc-aurèle; Daniel Bichet; Jean Spénard; Lyne Larivière; Daniel Plante; Gilles Caillé

• Publisher: John Wiley and Sons
• Year: 1991
• Tongue: English
• Weight: 330 KB
• Volume: 12
• Category: Article
• ISSN: 0142-2782
• DOI: 10.1002/bdd.2510120203

✦ Synopsis

The pharmacokinetics of diltiazem were studied in seven patients with chronic renal failure (CRF) not requiring dialysis and in three healthy volunteers after a rapid i.v. infusion of 20mg. Mean plasma concentrations at the end of infusion were 3.15 times higher in patients with CRF than in healthy volunteers. From 0.5 to 12h post-infusion, the difference remained between 25 per cent and 73 per cent. Mean AUC&, was statistically greater in patients than in volunteers while mean V area, CL,,,, and CL,, were statistically lower. The tHo and tYIB values were not significantly (p > 0.05) different between patients and volunteers. Renal excretion was statistically more important in volunteers (6.6 per cent of the dose) than in patients (1-2 per cent of the dose). We therefore conclude that CRF does not influence tYIB of diltiazem but it interferes with the extent and possibly the rate of its extravascular distribution. That could result in transient high plasma concentrations after rapid i.v. infusion.